Over the last 7 days, the United States market has dropped 1.5%, yet it has shown resilience with an 18% increase over the past year and an annual earnings growth forecast of 17%. In such a fluctuating environment, growth stocks with high insider ownership can be appealing as they often indicate strong confidence from those closest to the company in its long-term potential.

Top 10 Growth Companies With High Insider Ownership In The United States

Name	Insider Ownership	Earnings Growth
Uxin (UXIN)	34.3%	69.4%
Upstart Holdings (UPST)	13.9%	65.6%
Precigen (PGEN)	11.7%	55.4%
Karman Holdings (KRMN)	14.5%	54%
Hinge Health (HNGE)	15.7%	27.1%
Himax Technologies (HIMX)	29.2%	70.2%
Dave (DAVE)	17.7%	23%
Carlyle Group (CG)	27.5%	20.5%
Astera Labs (ALAB)	10%	33.2%
Almonty Industries (ALM)	10.8%	37.1%

We're going to check out a few of the best picks from our screener tool.

Ramaco Resources (METC)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Ramaco Resources, Inc. focuses on the development, operation, and sale of metallurgical coal with a market capitalization of approximately $695.72 million.

Operations: The company generates revenue primarily through its metallurgical coal segment, which accounted for $515.42 million.

Insider Ownership: 11%

Revenue Growth Forecast: 22.2% p.a.

Ramaco Resources is positioned as a growth company with significant insider ownership, benefiting from projected revenue growth of 22.2% annually, surpassing the US market average. Despite recent losses and reduced production guidance, Ramaco's strategic alliances in rare earth minerals could enhance its growth trajectory. The company has entered multiple non-binding MOUs to explore critical mineral supply opportunities from its Brook Mine project, potentially strengthening domestic supply chains for strategic technologies and supporting future profitability through diversification into high-demand sectors.

Prothena (PRTA)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Prothena Corporation plc is a late-stage clinical biotechnology company dedicated to discovering and developing novel therapies for diseases caused by protein dysregulation, with a market cap of approximately $485.13 million.

Operations: The company generates revenue primarily from its biotechnology segment, amounting to $54.53 million.

Insider Ownership: 19.3%

Revenue Growth Forecast: 33.4% p.a.

Prothena's substantial insider ownership aligns with its strong growth prospects, as revenue is forecast to grow 33.4% annually, outpacing the US market. Recent earnings showed a significant improvement in net income for the first half of 2026, despite a quarterly revenue dip. Insiders have been actively buying shares recently, and the company completed a notable share buyback program. Prothena trades significantly below its estimated fair value, suggesting potential investment appeal.

Finance of America Companies (FOA)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Finance of America Companies Inc. is a financial services holding company offering home equity-based financing solutions for modern retirement in the United States, with a market cap of $347 million.

Operations: The company generates revenue from its Portfolio Management segment, which contributes $110.55 million, and Retirement Solutions segment, contributing $279.39 million.

Insider Ownership: 22.2%

Revenue Growth Forecast: 29.8% p.a.

Finance of America Companies demonstrates potential with high insider ownership and forecasted revenue growth of 29.8% per year, surpassing the US market average. While recent earnings showed a decline in net income for Q2 2026 compared to the previous year, the company is expected to become profitable within three years. Recent changes in company bylaws and incorporation aim to streamline governance, although debt coverage by operating cash flow remains a concern.

Summing It All Up

• Click this link to deep-dive into the 181 companies within our Fast Growing US Companies With High Insider Ownership screener.
• Searching for a Fresh Perspective? AI is about to change healthcare. These 131 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.